Use of Laser Assisted New Attachment Procedure and Low Level Laser Therapy for Periodontitis Patients (LANAP LLLT)

January 1, 2021 updated by: Fadime KAYA DADAS, Izmir Katip Celebi University

Evaluation of Efficacy of LANAP and Adjunctive LLLT Application in the Treatment of Periodontitis: A Randomized Controlled Clinical Study

In this study, it is evaluated the effects of laser assisted new attachment procedure (LANAP) and low level laser therapy (LLLT) and on clinical, biochemical and radiographic parameters in addition to non-surgical periodontal treatment (NSPT).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study was designed as a randomized-controlled, single-blind and parallel design consisting of 80 patients with chronic periodontitis. Study consists of 4 groups, with 20 patients in each group. Group 1 received only NSPT, Group 2 received NSPT+LANAP, Group 3 received NSPT+LLLT, and Group 4 received NSPT+LANAP+LLLT. Clinical measurements of patients and gingival crevicular fluid (GCF) were taken before treatment and after 1 and 3 months. In GCF, interleukin-1beta, interleukin-10 and vascular endothelial growth factor were analyzed. Standard periapical radiographs were taken for radiographic measurements.

In moderate (4-6 mm) and deep pockets (7 mm and above), it was found that all groups treated with laser significantly decrease pocket depth (PD) and clinic attachment level (CAL) compared to Group 1. Group 3 caused significantly less gingival recession than all other groups. There was no statistical difference between the groups in biochemical markers. Radiographic analysis revealed that only Group 2 achieved significant bone filling compared to Group 1.

Bot LANAP and LLLT application in the deep pockets provide an additional contribution to NSPT. It has been found that LLLT administration leads to decrease in PD by creating a minimum recession.

Study Type

Interventional

Enrollment (Actual)

89

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Izmir, Turkey, 35000
        • Katip Celebi University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 70 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • periodontitis of periodontal stage II, III, or IV with grades B
  • with at least 12 teeth in the mouth and had ≥4 teeth but not all of them in the same quadrant
  • with Probing depth of ≥5 mm, Clinical attachment level of ≥4 mm
  • radiographic evidence of alveolar bone loss

Exclusion Criteria:

  • smoking
  • pregnancy and lactation
  • using antibiotics in the last 6 months and anti-inflammatory drugs in the last 3rd months,
  • having the systemic disease and the use of the drug that will affect the periodontal condition, having restoration of the adjacent tooth to be collected gingival crevicular fluid

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Control Group
scaling and root planning (SRP) was applied.
For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
ACTIVE_COMPARATOR: LANAP Group
After scaling and polishing, three LANAP stages were performed : In the first stage, Nd:YAG laser was applied. In the second stage, full mouth SRP procedure was performed. In the third stage, Nd:YAG laser was applied again.
For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
ACTIVE_COMPARATOR: LLLT Group
after SRP Low Level Laser Therapy was performed using Nd:YAG laser.
For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
ACTIVE_COMPARATOR: LANAP+LLLT Group
after scaling both LANAP and LLLT were applied.
For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical attachment level gain
Time Frame: Baseline
The clinical attachment level is determined by measuring the distance from the cemento-enamel junction to the gingival margin and adding the pocket depth to it.
Baseline
Clinical attachment level gain
Time Frame: 1 month
The clinical attachment level is determined by measuring the distance from the cemento-enamel junction to the gingival margin and adding the pocket depth to it.
1 month
Clinical attachment level gain
Time Frame: 3 month
The clinical attachment level is determined by measuring the distance from the cemento-enamel junction to the gingival margin and adding the pocket depth to it.
3 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Probing depth
Time Frame: Baseline
It is determined by measuring the distance from the gingival margin to the pocket base
Baseline
Probing depth
Time Frame: 1 Month
It is determined by measuring the distance from the gingival margin to the pocket base
1 Month
Probing depth
Time Frame: 3 Month
It is determined by measuring the distance from the gingival margin to the pocket base
3 Month
Gingival index
Time Frame: Baseline
For assessing severity of gingivitis, and its location by examining qualitative changes of gingival tissues
Baseline
Gingival index
Time Frame: 1 Month
For assessing severity of gingivitis, and its location by examining qualitative changes of gingival tissues
1 Month
Gingival index
Time Frame: 3 Month
For assessing severity of gingivitis, and its location by examining qualitative changes of gingival tissues
3 Month
Plaque index
Time Frame: Baseline
This index measures the thickness of plaque on gingival one third
Baseline
Plaque index
Time Frame: 1 Month
This index measures the thickness of plaque on gingival one third
1 Month
Plaque index
Time Frame: 3 Month
This index measures the thickness of plaque on gingival one third
3 Month
Bleeding on probing
Time Frame: Baseline
In this index, probing is performed by gently walking around the pocket and bleeding is evaluated. As a result of probing, evaluation is made by looking at the presence or absence of bleeding in the gingiva.
Baseline
Bleeding on probing
Time Frame: 1 Month
In this index, probing is performed by gently walking around the pocket and bleeding is evaluated. As a result of probing, evaluation is made by looking at the presence or absence of bleeding in the gingiva.
1 Month
Bleeding on probing
Time Frame: 3 Month
In this index, probing is performed by gently walking around the pocket and bleeding is evaluated. As a result of probing, evaluation is made by looking at the presence or absence of bleeding in the gingiva.
3 Month
Interleukin-1beta
Time Frame: Baseline
IL-1 is a protein produced mainly by monocytes and macrophages as a polyclonal activator.
Baseline
Interleukin-1beta
Time Frame: 1 Month
IL-1 is a protein produced mainly by monocytes and macrophages as a polyclonal activator.
1 Month
Interleukin-1beta
Time Frame: 3 Month
IL-1 is a protein produced mainly by monocytes and macrophages as a polyclonal activator.
3 Month
Interleukin-10
Time Frame: Baseline
IL-10 is an 18 kilodalton (KD) cytokine with a wide variety of (pleiotropic) effects.
Baseline
Interleukin-10
Time Frame: 1 Month
IL-10 is an 18 kilodalton (KD) cytokine with a wide variety of (pleiotropic) effects.
1 Month
Interleukin-10
Time Frame: 3 Month
IL-10 is an 18 kilodalton (KD) cytokine with a wide variety of (pleiotropic) effects.
3 Month
vascular endothelial growth factor (VEGF)
Time Frame: Baseline
VEGF is a glycoprotein molecule that is a potential stimulator of angiogenesis.
Baseline
vascular endothelial growth factor (VEGF)
Time Frame: 1 Month
VEGF is a glycoprotein molecule that is a potential stimulator of angiogenesis.
1 Month
vascular endothelial growth factor (VEGF)
Time Frame: 3 Month
VEGF is a glycoprotein molecule that is a potential stimulator of angiogenesis.
3 Month
Radiographic bone fill
Time Frame: Baseline
The effects of treatments on bone loss were evaluated by making some measurements on periapical radiography.
Baseline
Radiographic bone fill
Time Frame: 1 Month
The effects of treatments on bone loss were evaluated by making some measurements on periapical radiography.
1 Month
Radiographic bone fill
Time Frame: 3 Month
The effects of treatments on bone loss were evaluated by making some measurements on periapical radiography.
3 Month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Serhat Köseoğlu, Study Manager

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

October 2, 2017

Primary Completion (ACTUAL)

April 16, 2018

Study Completion (ACTUAL)

June 15, 2018

Study Registration Dates

First Submitted

December 30, 2020

First Submitted That Met QC Criteria

January 1, 2021

First Posted (ACTUAL)

January 5, 2021

Study Record Updates

Last Update Posted (ACTUAL)

January 5, 2021

Last Update Submitted That Met QC Criteria

January 1, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Clinical Trials on Nd:YAG laser

3
Subscribe